{"id":"sublingual-film-containing-igalmi","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2109194","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Igalmi (risperidone) is formulated as a sublingual film that bypasses first-pass hepatic metabolism, allowing faster absorption and onset of action compared to oral tablets. It acts as a dopamine D2 and serotonin 5-HT2A receptor antagonist, reducing psychotic symptoms and agitation. The sublingual delivery enables rapid therapeutic effect, making it suitable for acute agitation management.","oneSentence":"Igalmi is a fast-acting atypical antipsychotic that rapidly dissolves under the tongue to block dopamine and serotonin receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:54.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation associated with schizophrenia or bipolar disorder"}]},"trialDetails":[{"nctId":"NCT06041646","phase":"PHASE4","title":"Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2023-10-02","conditions":"Bipolar Disorder, Schizophrenia, Agitation,Psychomotor","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexmedetomidine","BXCL501"],"phase":"marketed","status":"active","brandName":"Sublingual film containing Igalmi","genericName":"Sublingual film containing Igalmi","companyName":"BioXcel Therapeutics Inc","companyId":"bioxcel-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Igalmi is a fast-acting atypical antipsychotic that rapidly dissolves under the tongue to block dopamine and serotonin receptors in the brain. Used for Acute agitation associated with schizophrenia or bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}